{"id":"abobotulinumtoxina-abo","safety":{"commonSideEffects":[{"rate":"7-13%","effect":"Headache"},{"rate":"1-3%","effect":"Injection site pain"},{"rate":"1-3%","effect":"Eyelid ptosis"},{"rate":"1-2%","effect":"Brow ptosis"},{"rate":"1-2%","effect":"Injection site edema"},{"rate":"1-2%","effect":"Injection site erythema"}]},"_chembl":{"chemblId":"CHEMBL2108570","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"AbobotulinumtoxinA is a botulinum toxin serotype A that irreversibly cleaves SNAP-25, a protein essential for acetylcholine vesicle fusion and release. This prevents neuromuscular transmission, resulting in temporary muscle relaxation lasting 3-4 months. The effect is localized to injected muscles and is reversible as new nerve terminals form.","oneSentence":"AbobotulinumtoxinA blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:26:25.747Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe glabellar lines (frown lines)"},{"name":"Moderate to severe lateral canthal lines (crow's feet)"},{"name":"Moderate to severe forehead lines"}]},"trialDetails":[{"nctId":"NCT03805152","phase":"PHASE3","title":"Abobotulinum Toxin and Neubotulinum Toxin Injection in Cerivical Dystonia","status":"COMPLETED","sponsor":"Department of Medical Services Ministry of Public Health of Thailand","startDate":"2019-10-25","conditions":"Cervical Dystonia","enrollment":52},{"nctId":"NCT04756882","phase":"PHASE2, PHASE3","title":"Clinical Evaluation of the Efficacy OF Botulinum Toxin A for Improving Facial Scars","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2020-11-18","conditions":"Hypertrophic Scarring","enrollment":12},{"nctId":"NCT01732809","phase":"PHASE4","title":"Fields Of Effects Of Two Commercial Preparations Of Botulinum Toxin Type A At Equal Labeled Unit Doses","status":"COMPLETED","sponsor":"Hexsel Dermatology Clinic","startDate":"2011-01","conditions":"Skin Wrinkling","enrollment":19}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":62,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Dysport®"],"phase":"marketed","status":"active","brandName":"AbobotulinumtoxinA (ABO)","genericName":"AbobotulinumtoxinA (ABO)","companyName":"Hexsel Dermatology Clinic","companyId":"hexsel-dermatology-clinic","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AbobotulinumtoxinA blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. Used for Moderate to severe glabellar lines (frown lines), Moderate to severe forehead lines, Moderate to severe crow's feet.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}